One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

More Than 50 New Medicines for HIV treatment to be Developed

17 July 2017 09:36

More  than 50 new drugs for HIV treatment are developed all over the World, said the Medicines in Development report by The Pharmaceutical Research and Manufacturers of America (PhRMA).

The majority of people living with HIV take not only one drug, but use combination of two or three drugs in one pill. Using one pill is easier - patient have few chances to forget about his drug intake and a few chances to improve his health and to increase the drug adherence.

Now there are about 45 drugs for HIv treatment and care approved in the USA, more than 50 new medicines are being developed. New medicines will be useful not only for HIV-positive patients, but also for broader public health, biopharmaceutical industry and health care community.

“Thanks to the hard work and dedication of countless individuals – from biopharmaceutical researchers, to those patients enrolled in clinical trials – we have seen an 88 percent decline in the HIV/AIDS death rate since the 1990s, and an estimated 862,000 premature HIV/AIDS deaths have been prevented in the United States. While we have made great progress, there is more to be done, which is why the 52 medicines and vaccines in development offer tremendous hope and inspiration that an AIDS-free generation may one day be in reach.” - said Stephen J. Ubl, president and chief executive officer of PhRMA.


Latest News

DIY faecal transplants carry risks including HIV and hepatitis

Faecal transplants have been used in medical settings to tackle superbugs, but following YouTube videos at home is too risky, say researchers.

16 February 15:30

Gilead's total revenues were $26.1 billion in 2017

For the fourth quarter 2017, Gilead Sciences total revenues were $5.9 billion. For the full year 2017, total revenues were $26.1 billion. HIV and HBV product sales for the full year 2017 were $14.2 billion. Genvoya represents the most successful HIV launch in the U.S. and ...

16 February 09:31

Key vaginal bacteria identified that increase HIV risk in women

Women's risk of HIV significantly associated with key bacteria and their abundance in the vagina.

15 February 16:35

Experimental Drug Kills Flu Virus in a Single Day

Shionogi developed baloxavir marboxil by leveraging discoveries made in anti-HIV drugs, targeting a different kind of enzyme and preventing cells from susceptibility to virus infection in the first place.

15 February 13:27